# Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers

> **NCT02497820** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 1800 (estimated)

## Conditions studied

- Lynch Syndrome I (Site-specific Colonic Cancer)

## Interventions

- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT02497820
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2016-09
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2016-08-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02497820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02497820, "Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02497820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*